Artiva Biotherapeutics (NASDAQ:ARTV) Director Ra Capital Management, L.P. Acquires 15,102 Shares of Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. acquired 15,102 shares of Artiva Biotherapeutics stock in a transaction that occurred on Friday, July 10th. The shares were purchased at an average price of $8.97 per share, with a total value of $135,464.94. Following the purchase, the director owned 16,811,021 shares in the company, valued at $150,794,858.37. This represents a 0.09% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, July 13th, Ra Capital Management, L.P. bought 6,552 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $8.94 per share, with a total value of $58,574.88.
• On Friday, June 26th, Ra Capital Management, L.P. purchased 1,876 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $8.98 per share, for a total transaction of $16,846.48.
• On Thursday, June 25th, Ra Capital Management, L.P. purchased 31,000 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $8.88 per share, for a total transaction of $275,280.00.
• On Tuesday, June 16th, Ra Capital Management, L.P. purchased 124,893 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $8.89 per share, for a total transaction of $1,110,298.77.
• On Monday, June 15th, Ra Capital Management, L.P. acquired 15,414 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $8.99 per share, with a total value of $138,571.86.
• On Friday, June 12th, Ra Capital Management, L.P. acquired 391,019 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $8.57 per share, with a total value of $3,351,032.83.
• On Thursday, June 11th, Ra Capital Management, L.P. bought 548,580 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $7.91 per share, for a total transaction of $4,339,267.80.
• On Wednesday, June 10th, Ra Capital Management, L.P. purchased 103 shares of Artiva Biotherapeutics stock. The stock was acquired at an average price of $7.00 per share, with a total value of $721.00.
• On Tuesday, June 9th, Ra Capital Management, L.P. purchased 479,039 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $6.91 per share, with a total value of $3,310,159.49.
• On Monday, May 11th, Ra Capital Management, L.P. purchased 6,510,416 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $11.52 per share, with a total value of $74,999,992.32.

Artiva Biotherapeutics Price Performance

Shares of ARTV stock traded up $0.42 during trading hours on Tuesday, reaching $9.35. 431,462 shares of the company’s stock were exchanged, compared to its average volume of 556,605. Artiva Biotherapeutics, Inc. has a 1 year low of $2.04 and a 1 year high of $14.53. The stock’s fifty day moving average price is $9.01 and its two-hundred day moving average price is $7.02.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). As a group, equities analysts forecast that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. HC Wainwright raised their price objective on Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Artiva Biotherapeutics in a report on Tuesday, May 26th. Wall Street Zen lowered Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $41.00 price target on shares of Artiva Biotherapeutics in a report on Monday, June 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Artiva Biotherapeutics has an average rating of “Moderate Buy” and an average price target of $39.00.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ARTV. Citadel Advisors LLC raised its stake in shares of Artiva Biotherapeutics by 419.3% during the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock valued at $2,291,000 after buying an additional 644,658 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Artiva Biotherapeutics by 14,463.5% in the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after buying an additional 117,733 shares during the last quarter. Marshall Wace LLP acquired a new stake in Artiva Biotherapeutics during the fourth quarter worth about $341,000. Jane Street Group LLC acquired a new stake in Artiva Biotherapeutics during the second quarter worth about $67,000. Finally, Landscape Capital Management L.L.C. purchased a new position in Artiva Biotherapeutics during the third quarter valued at approximately $112,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.